Charles River
CRL
300.30
-4.66
-1.53%
Charles River
US · CRL
#1174 by market cap
Listed 1970
300.30
-4.66
-1.53%
Live - 5344 symbols - heartbeat 502s ago
· 2026-10-08 07:05
Pre-market
299.00
-0.43%
After-hours
300.30
0.00%
- Market cap
- 14.34B
- P/E (TTM)i
- -62.56
- P/Bi
- 5.05
- EPSi
- -2.91
- Div yieldi
- 0.00%
- 52W posi
- 82%
Reader sentiment
Are you bullish or bearish on CRL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.27, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -0.85% YoY
Margins
- Gross margin
- 32.96%
- Operating margin
- 9.99%
- Net margin
- -3.59%
Key ratios & quality
- Altman Z-Scorei
- 3.27
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.27B | 2.62B | 2.92B | 3.54B | 3.98B | 4.13B | 4.05B | 4.02B |
| Gross profit | 840.07M | 958.31M | 1.07B | 1.33B | 1.46B | 1.50B | 1.33B | 1.32B |
| Selling & admin expenses | 443.85M | 517.62M | 528.94M | 619.92M | 665.10M | 747.86M | 751.00M | 743.07M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 331.38M | 351.15M | 432.73M | 589.86M | 650.98M | 617.26M | 442.35M | 401.14M |
| Pretax profit | 281.68M | 304.08M | 447.11M | 480.71M | 622.99M | 581.28M | 93.11M | -99.50M |
| Tax | 54.46M | 50.02M | 81.81M | 81.87M | 130.38M | 100.91M | 67.82M | 42.66M |
| Net profit | 228.72M | 254.06M | 365.31M | 398.84M | 492.61M | 480.37M | 25.29M | -142.16M |
| Basic EPS | 5 | 5 | 7 | 8 | 10 | 9 | 0 | -3 |
| Diluted EPS | 4.62 | 5.07 | 7.20 | 7.60 | 9.48 | 9.22 | 0.20 | -2.91 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -- | -- | -- | -- | -- | -- |
| Pretax profit | -- | -- | -- | -- | -- | -- |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -- | -- | -- | -- | -- | -- |
| Basic EPS | -- | -- | -- | -- | -- | -- |
| Diluted EPS | -- | -- | -- | -- | -- | -- |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 897.84M | 1.02B | 1.20B | 1.27B | 1.44B | 1.61B | 1.40B | 1.45B |
| Cash & ST investments | 196.33M | 238.96M | 229.45M | 241.21M | 233.91M | 276.77M | 194.61M | 213.77M |
| Inventory | 127.89M | 160.66M | 185.70M | 199.15M | 255.81M | 380.26M | 278.54M | 299.10M |
| Total assets | 3.86B | 4.69B | 5.49B | 7.02B | 7.60B | 8.20B | 7.53B | 7.14B |
| Total current liabilities | 558.22M | 710.18M | 839.75M | 1.03B | 1.09B | 1.06B | 994.10M | 1.12B |
| Short-term debt | 31.42M | 58.90M | 74.89M | -- | -- | -- | -- | -- |
| Long-term debt | 1.61B | 1.82B | 1.90B | 2.66B | 2.71B | 2.65B | 2.21B | 2.11B |
| Total liabilities | 2,517,576,000.00 | 3,026,315,000.00 | 3,347,163,000.00 | 4,432,300,000.00 | 4,579,265,000.00 | 4,536,003,000.00 | 4,020,267,000.00 | 3,924,228,000.00 |
| Total equity | 1.34B | 1.67B | 2.14B | 2.59B | 3.02B | 3.66B | 3.51B | 3.21B |
| Retained earnings | 42.10M | 280.33M | 625.41M | 980.75M | 1.43B | 1.89B | 1.81B | 1.39B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.51B | 1.47B | 1.53B | 1.45B | 1.49B | 1.53B |
| Cash & ST investments | 229.36M | 182.82M | 207.10M | 213.77M | 191.83M | 192.03M |
| Inventory | 290.16M | 279.55M | 302.55M | 299.10M | 359.72M | 346.26M |
| Total assets | 7.58B | 7.56B | 7.51B | 7.14B | 7.73B | 7.53B |
| Total current liabilities | 1.05B | 1.08B | 1.12B | 1.12B | 1.09B | 1.13B |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | 2.51B | 2.33B | 2.19B | 2.11B | 2.66B | 2.62B |
| Total liabilities | 4,340,584,000.00 | 4,160,959,000.00 | 4,062,995,000.00 | 3,924,228,000.00 | 4,741,995,000.00 | 4,643,618,000.00 |
| Total equity | 3.24B | 3.40B | 3.45B | 3.21B | 2.99B | 2.89B |
| Retained earnings | 1.84B | 1.89B | 1.94B | 1.39B | 1.37B | 1.37B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 441.14M | 480.94M | 546.58M | 760.80M | 619.64M | 683.90M | 734.58M | 737.65M |
| Depreciation & amortization | 161.78M | 198.10M | 234.92M | 265.54M | 303.87M | 314.12M | 361.74M | 403.31M |
| Free cash flow | 301.09M | 340.42M | 380.02M | 532.03M | 294.91M | 365.37M | 501.61M | 518.49M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -13.85M | -18.09M | -23.98M | -40.71M | -38.65M | -24.16M | -119.18M | -360.67M |
| Ending cash balance | 197.32M | 240.05M | 233.12M | 246.31M | 241.21M | 284.48M | 205.57M | 216.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 171.70M | 204.60M | 213.83M | 147.52M | 41.08M | 179.73M |
| Depreciation & amortization | 120.36M | 119.51M | 85.16M | 78.28M | 67.15M | 67.29M |
| Free cash flow | 112.37M | 169.31M | 178.25M | 58.57M | -14.83M | 148.62M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -353.13M | -7.35M | -93.00K | -96.00K | -208.29M | -115.60M |
| Ending cash balance | 231.73M | 184.74M | 209.22M | 216.00M | 198.20M | 240.58M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 19.16 | 17.07 | 19.43 | 16.82 | 17.65 | 14.44 | 0.29 | -4.36 |
| ROA %i | 6.67 | 5.90 | 7.15 | 6.25 | 6.65 | 6.01 | 0.13 | -1.97 |
| ROIC %i | 10.71 | 9.08 | 10.95 | 9.26 | 9.24 | 9.16 | 1.52 | -1.15 |
| 5-year avg ROE %i | 18.51 | 18.06 | 17.70 | 17.12 | 18.03 | 17.08 | 13.73 | 8.97 |
| EBIT margin %i | 15.24 | 13.92 | 18.25 | 15.67 | 17.16 | 17.39 | 5.42 | 0.19 |
| FCF / sales %i | 13.29 | 12.99 | 13.00 | 15.03 | 7.42 | 8.85 | 12.39 | 12.91 |
| Current ratioi | 1.61 | 1.44 | 1.43 | 1.23 | 1.32 | 1.52 | 1.41 | 1.29 |
| Quick ratioi | 1.20 | 1.06 | 1.01 | 0.86 | 0.90 | 1.00 | 0.92 | 0.82 |
| Debt / assetsi | 43.26 | 43.15 | 39.34 | 41.52 | 40.74 | 37.42 | 36.18 | 36.02 |
| LT debt / equityi | 124.24 | 120.27 | 98.61 | 115.06 | 104.06 | 85.25 | 78.69 | 81.22 |
| Interest coveragei | 5.42 | 5.99 | 6.17 | 7.50 | 11.51 | 5.25 | 1.74 | 0.07 |
| Revenue CAGR (3Y) %i | 18.46 | 15.95 | 16.32 | 16.03 | 14.90 | 12.20 | 4.59 | 0.33 |
| Net income CAGR (3Y) %i | 14.88 | 17.65 | 43.47 | 19.98 | 24.49 | 9.22 | -70.25 | -- |
| FCF CAGR (3Y) %i | 7.60 | 9.17 | 17.27 | 20.90 | -4.67 | -1.30 | -1.94 | 20.69 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -0.92 | -1.96 | -2.32 | -4.36 | -6.02 | -7.70 |
| ROA %i | -0.40 | -0.89 | -1.08 | -1.97 | -2.41 | -3.16 |
| ROIC %i | 0.80 | 0.21 | -0.08 | -1.15 | -2.03 | -2.96 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 3.71 | 2.44 | 2.22 | 0.19 | -1.48 | -1.94 |
| FCF / sales %i | 14.00 | 14.36 | 13.51 | 12.91 | 9.72 | 9.27 |
| Current ratioi | 1.43 | 1.36 | 1.37 | 1.29 | 1.36 | 1.35 |
| Quick ratioi | 0.94 | 0.88 | 0.84 | 0.82 | 0.82 | 0.80 |
| Debt / assetsi | 39.38 | 36.85 | 34.98 | 36.02 | 39.54 | 40.20 |
| LT debt / equityi | 93.47 | 83.08 | 77.19 | 81.22 | 103.93 | 106.62 |
| Interest coveragei | 1.25 | 0.84 | 0.80 | 0.07 | -0.56 | -0.73 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Discovery and Safety Assessment (DSA) is the largest reported line at 60.40% of revenue, across 3 reported segments.
- Research Models and Services (RMS) follows at 20.86%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Discovery and Safety Assessment (DSA)60.40%
Research Models and Services (RMS)20.86%
Manufacturing18.73%
Quote time 2026-10-08 07:05:05 · For reference only, not investment advice and not tailored to your situation.